AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16003036 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (squats on a 25 degrees decline board, 3 x 15 repetitions twice daily for 12 weeks)
Number of subjects: 29
Study 16003036 — intervention group
Group type: COMPARATOR
Intervention: Control group (trained as usual)
Number of subjects: 29
Study 12766127 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in ulcer area greater than the 4-week median
Number of subjects: 203
Study 12766127 — intervention group
Group type: COMPARATOR
Intervention: Reduction in ulcer area less than the 4-week median
Number of subjects: 203
Study 12766127 — intervention group
Group type: EXPERIMENTAL
Intervention: Healers (absolute change in ulcer area at 4 weeks)
Number of subjects: 203
Study 12766127 — intervention group
Group type: COMPARATOR
Intervention: Nonhealers (absolute change in ulcer area at 4 weeks)
Number of subjects: 203
Study 12766127 — intervention group
Group type: EXPERIMENTAL
Intervention: Healed patients (percent change in wound area at 4 weeks)
Number of subjects: 203
Study 12766127 — intervention group
Group type: COMPARATOR
Intervention: Failed to heal patients (percent change in wound area at 4 weeks)
Number of subjects: 203
Study 10575499 — intervention group
Group type: EXPERIMENTAL
Intervention: PAA (Preanaesthetic Assessment) followed by PAV (Preanaesthetic Visit)
Number of subjects: 296
Study 10575499 — intervention group
Group type: COMPARATOR
Intervention: PAV (without previous PAA)
Number of subjects: 296
Study 8909736 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium 100 mg (preoperative administration)
Number of subjects: 21
Study 8909736 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium 100 mg (postoperative administration)
Number of subjects: 21
Study 8909736 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac sodium 100 mg (both pre- and postoperative)
Number of subjects: 21
Study 1869646 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical masoprocol applied twice a day for 14 to 28 days
Number of subjects: 113
Study 1869646 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 113
Study 1869646 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical masoprocol
Number of subjects: 113
Study 6213376 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg MPA with 250 mg testosterone enanthate (TE) monthly injection
Number of subjects: 25
Study 31608551 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin
Number of subjects: 16
Study 31608551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31608551 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 16
Study 31264912 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination (at least one dose)
Number of subjects: 375
Study 31264912 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination after age 18
Number of subjects: 375
Study 31264912 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination after first vaginal intercourse
Number of subjects: 375
Study 31264912 — intervention group
Group type: EXPERIMENTAL
Intervention: College education
Number of subjects: 375
Study 31264912 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16/18 positivity
Number of subjects: 375
Study 29473223 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal placement of implants
Number of subjects: 48
Study 29473223 — intervention group
Group type: COMPARATOR
Intervention: Epicrestal placement of implants
Number of subjects: 48
Study 29473223 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 27447245 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep transcranial magnetic stimulation (TMS) with H-1 coil, 120% target stimulation intensity, 18 Hz, 55 trains of 2-second duration, total 1980 pulses.
Number of subjects: 1
Study 27447245 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 1
Study 24585164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwaste needleless setup
Number of subjects: 90
Study 24585164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwaste syringe setup
Number of subjects: 90
Study 24585164 — intervention group
Group type: COMPARATOR
Intervention: Standard setup (control group)
Number of subjects: 90
Study 24585164 — intervention group
Group type: EXPERIMENTAL
Intervention: Needleless group
Number of subjects: 90
Study 24585164 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe group
Number of subjects: 90
Study 24585164 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial catheter samples
Number of subjects: 90
Study 23044236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/day ETV (group A)
Number of subjects: 57
Study 23044236 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/day ETV maleate (group B)
Number of subjects: 57
Study 19562395 — intervention group
Group type: EXPERIMENTAL
Intervention: First causal relation categories
Number of subjects: 0
Study 19562395 — intervention group
Group type: EXPERIMENTAL
Intervention: Second causal relation categories
Number of subjects: 0
Study 18556248 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (n=13)
Number of subjects: 28
Study 18556248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 28
Study 15983801 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ng/ml ketamine
Number of subjects: 12
Study 15983801 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ng/ml ketamine
Number of subjects: 12
Study 15983801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15983801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (50 ng/ml or 100 ng/ml)
Number of subjects: 12
Study 11916440 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm retrograde continuous blood cardioplegia (RCBC)
Number of subjects: 22
Study 11916440 — intervention group
Group type: COMPARATOR
Intervention: Cold retrograde continuous blood cardioplegia (RCBC)
Number of subjects: 22
Study 10606501 — intervention group
Group type: EXPERIMENTAL
Intervention: BrAC = 0.05%
Number of subjects: 11
Study 10606501 — intervention group
Group type: EXPERIMENTAL
Intervention: BrAC = 0.1%
Number of subjects: 11
Study 10606501 — intervention group
Group type: COMPARATOR
Intervention: BrAC = 0.0% (no-alcohol placebo)
Number of subjects: 11
Study 9384642 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron therapy
Number of subjects: 0
Study 9384642 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 1678941 — intervention group
Group type: COMPARATOR
Intervention: Repetitive injections of vecuronium (Group 1)
Number of subjects: 22
Study 1678941 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive closed-loop feedback system (Group 2)
Number of subjects: 22
Study 6343664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (CTT) 2g daily
Number of subjects: 150
Study 6343664 — intervention group
Group type: COMPARATOR
Intervention: Cefmetazole (CMZ) 4g daily
Number of subjects: 150
Study 29962090 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based acceptance and commitment therapy (ACT) program (YOLO), 4 weeks
Number of subjects: 130
Study 27255908 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot assisted gait training (RAGT)
Number of subjects: 0
Study 27255908 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional physical therapy program conducted over-ground (fPT)
Number of subjects: 0
Study 27255908 — intervention group
Group type: EXPERIMENTAL
Intervention: RAGT and fPT combined
Number of subjects: 0
Study 27255908 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy only
Number of subjects: 0
Study 25421843 — intervention group
Group type: EXPERIMENTAL
Intervention: Training courses on breastfeeding during pregnancy (Group A)
Number of subjects: 77
Study 25421843 — intervention group
Group type: COMPARATOR
Intervention: No training courses on breastfeeding (Group B)
Number of subjects: 77
Study 22118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedure IVUS minimum lumen area
Number of subjects: 318
Study 22118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedure IVUS minimum stent area
Number of subjects: 318
Study 22118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprocedure IVUS reference average lumen area
Number of subjects: 318
Study 22118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum stent area as a predictor of angiographic restenosis
Number of subjects: 318
Study 22118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus prevalence
Number of subjects: 318
Study 22118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stent use prevalence
Number of subjects: 318
Study 22118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated plaque behind the stent struts
Number of subjects: 318
Study 20438662 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert Example
Number of subjects: 134
Study 20438662 — intervention group
Group type: COMPARATOR
Intervention: Advanced Student Example
Number of subjects: 134
Study 17660490 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous VTE
Number of subjects: 227
Study 17660490 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE during chemotherapy
Number of subjects: 227
Study 16278629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combined spinal-epidural (CSE) anesthesia
Number of subjects: 100
Study 16278629 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 100
Study 11861034 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with conjugated estrogens 0.625 mg/day for 4 weeks
Number of subjects: 18
Study 11861034 — intervention group
Group type: COMPARATOR
Intervention: Thrombin-stimulated platelets (0.1 U/ml)
Number of subjects: 18
Study 11861034 — intervention group
Group type: COMPARATOR
Intervention: Thrombin-stimulated platelets (0.3 U/ml)
Number of subjects: 18
Study 10455479 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg once daily)
Number of subjects: 81
Study 10455479 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide (2.5 mg once daily)
Number of subjects: 81
Study 8719258 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CREAT)
Number of subjects: 6
Study 2611092 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal lignocaine (100 mg dose)
Number of subjects: 6
Study 2611092 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lignocaine (100 mg dose)
Number of subjects: 6
Study 937882 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (during the initial 3 days)
Number of subjects: 29
Study 937882 — intervention group
Group type: COMPARATOR
Intervention: Complete bed rest (for 5 days)
Number of subjects: 29
Study 937882 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (with heart failure)
Number of subjects: 29
Study 937882 — intervention group
Group type: COMPARATOR
Intervention: Complete bed rest (with heart failure)
Number of subjects: 29
Study 937882 — intervention group
Group type: EXPERIMENTAL
Intervention: Venography
Number of subjects: 29
Study 31245885 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylactic group (2 g of cefotiam during endoscopic injection)
Number of subjects: 107
Study 31245885 — intervention group
Group type: COMPARATOR
Intervention: On-demand group (no prophylactic antibiotics)
Number of subjects: 107
Study 31245885 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylactic group
Number of subjects: 107
Study 31245885 — intervention group
Group type: COMPARATOR
Intervention: On-demand group
Number of subjects: 107
Study 26314289 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face treatment
Number of subjects: 147
Study 26314289 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based treatment
Number of subjects: 147
Study 23996977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 5016
Study 23996977 — intervention group
Group type: COMPARATOR
Intervention: Minimal lifestyle intervention
Number of subjects: 5016
Study 23996977 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 5016
Study 23996977 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depression score
Number of subjects: 5016
Study 23996977 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-married status
Number of subjects: 5016
Study 23996977 — intervention group
Group type: EXPERIMENTAL
Intervention: Never self-weighing prior to enrollment
Number of subjects: 5016
Study 23883531 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Number of subjects: 45
Study 23883531 — intervention group
Group type: EXPERIMENTAL
Intervention: ProVisc
Number of subjects: 45
Study 23883531 — intervention group
Group type: EXPERIMENTAL
Intervention: DisCoVisc
Number of subjects: 45
Study 20458822 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional left atrial (LA) septal line ablation
Number of subjects: 34
Study 20458822 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein (PV) isolation with roof line, mitral isthmus line and coronary sinus ablation (Control group)
Number of subjects: 34
Study 20458822 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional LA septal line ablation
Number of subjects: 34
Study 18218295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 24
Study 18218295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17050889 — intervention group
Group type: COMPARATOR
Intervention: DHEA (men)
Number of subjects: 144
Study 17050889 — intervention group
Group type: COMPARATOR
Intervention: DHEA (women)
Number of subjects: 144
Study 17050889 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (men)
Number of subjects: 144
Study 14610119 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia with Lewy bodies (DLB)
Number of subjects: 78
Study 14610119 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 78
Study 14610119 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 78
Study 10933118 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone for 12 months
Number of subjects: 11
Study 10933118 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone for 6 months
Number of subjects: 11
Study 8874911 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.07 mg/kg)
Number of subjects: 103
Study 8874911 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 103
Study 7980751 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatology Nurse Practitioner (RNP)
Number of subjects: 70
Study 7980751 — intervention group
Group type: COMPARATOR
Intervention: Consultant Rheumatologist (CR)
Number of subjects: 70
Study 3246212 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg trimethoprim (TMP)
Number of subjects: 26
Study 3246212 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg cinoxacin (CNO)
Number of subjects: 26
Study 30900815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 g/d DHA+EPA
Number of subjects: 123
Study 30900815 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 g/d EPA+DHA
Number of subjects: 123
Study 30900815 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2 g/d ALA
Number of subjects: 123
Study 30900815 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2 g/d ALA
Number of subjects: 123
Study 30900815 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 123
Study 28511172 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐ATG/EVR (n = 85)
Number of subjects: 288
Study 28511172 — intervention group
Group type: EXPERIMENTAL
Intervention: BAS/EVR (n = 102)
Number of subjects: 288
Study 28511172 — intervention group
Group type: EXPERIMENTAL
Intervention: BAS/MPS (n = 101)
Number of subjects: 288
Study 29871266 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIT + drug group (sublingual immunotherapy with Dermatophagoides farinae drops and symptomatic therapy)
Number of subjects: 102
Study 29871266 — intervention group
Group type: COMPARATOR
Intervention: Drug group (mometasone furoate nasal spray and desloratadine tablets)
Number of subjects: 102
Study 23598691 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (50 mg per day for 4 months)
Number of subjects: 93
Study 23598691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 21854273 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine tapering schedule
Number of subjects: 892
Study 18955082 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance-trained athletes (END)
Number of subjects: 15
Study 18955082 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-trained athletes (POW)
Number of subjects: 15
Study 18955082 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 15
Study 18046666 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with ACEIs and ARBs
Number of subjects: 2100
Study 18046666 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with ACEIs or ARBs
Number of subjects: 2100
Study 14730412 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg deramciclane
Number of subjects: 15
Study 14730412 — intervention group
Group type: COMPARATOR
Intervention: 20 mg paroxetine
Number of subjects: 15
Study 11563590 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment and secondary prophylaxis during PBSCT
Number of subjects: 9
Study 11563590 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without IA history)
Number of subjects: 9
Study 8774617 — intervention group
Group type: EXPERIMENTAL
Intervention: BC-PC (buffy coat platelet concentrates)
Number of subjects: 36
Study 8774617 — intervention group
Group type: COMPARATOR
Intervention: SD-PC (single donor platelet concentrates)
Number of subjects: 36
Study 8774617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh PC (day 1)
Number of subjects: 36
Study 8774617 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored PC (day 2-3)
Number of subjects: 36
Study 8774617 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-stored PC (day 4-5)
Number of subjects: 36
Study 1338525 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (4 mg/l mixed into the cardioplegic solution)
Number of subjects: 54
Study 1338525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 6143538 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 5 mg
Number of subjects: 9
Study 6143538 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg
Number of subjects: 9
Study 6143538 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg
Number of subjects: 9
Study 6143538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31122493 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-careldopa (125 mg after initial doses of 62.5 mg)
Number of subjects: 593
Study 31122493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 31122493 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-careldopa
Number of subjects: 593
Study 30574253 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimproved water sources
Number of subjects: 469
Study 30574253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of hand washing at critical times
Number of subjects: 469
Study 30574253 — intervention group
Group type: EXPERIMENTAL
Intervention: Deepening method to take water from a water storage container
Number of subjects: 469
Study 30574253 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of two or more young siblings
Number of subjects: 469
Study 30574253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural residence
Number of subjects: 469
Study 30574253 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using latrine for disposal of child feces
Number of subjects: 469
Study 24344160 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 2865
Study 24344160 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 2865
Study 24344160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2865
Study 24990015 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory (WM) Training Program
Number of subjects: 14
Study 24990015 — intervention group
Group type: COMPARATOR
Intervention: Poetry‐based Stimulation Program
Number of subjects: 14
Study 22019079 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over left DLPFC
Number of subjects: 15
Study 22019079 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over right DLPFC
Number of subjects: 15
Study 22019079 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study 20003341 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care management with the addition of TENS
Number of subjects: 240
Study 20003341 — intervention group
Group type: COMPARATOR
Intervention: Primary care management (standard GP consultation, medication, advice and education)
Number of subjects: 240
Study 17567350 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube S
Number of subjects: 160
Study 17567350 — intervention group
Group type: COMPARATOR
Intervention: LMA‐ProSeal
Number of subjects: 160
Study 15451351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic measurements of the median nerve (cross-sectional area and flattening ratio)
Number of subjects: 131
Study 15451351 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic individuals)
Number of subjects: 131
Study 11472461 — intervention group
Group type: COMPARATOR
Intervention: Captopril (angiotensin converting enzyme inhibitor)
Number of subjects: 758
Study 11472461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (beta blocker)
Number of subjects: 758
Study 11472461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 758
Study 9735735 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-Up Active Wound Therapy
Number of subjects: 13
Study 9735735 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 13
Study 9270567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (n = 116) starting dose of 0.25 mg tid, titrated to at least 1.5 mg tid (maximum dose, 8 mg tid)
Number of subjects: 241